Trials / Not Yet Recruiting
Not Yet RecruitingNCT07489716
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
A Phase II Clinical Study on the Efficacy, Safety, and Pharmacokinetics of SHR-1826 for Injection in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1826 | SHR-1826 |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-08-01
- Completion
- 2028-12-01
- First posted
- 2026-03-24
- Last updated
- 2026-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07489716. Inclusion in this directory is not an endorsement.